We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Pain Reliever from Snail Venom

By Biotechdaily staff writers
Posted on 15 Jul 2002
Researchers have discovered that a compound from a toxic marine snail, an often deadly mollusk found on the Great Barrier Reef, is more powerful and longer lasting than morphine but is not addictive and lacks morphine's side effects. More...
The discovery was announced at the annual meeting of the International Society for Toxicology in Cairns, Australia.

The compound, called ACV1, is made from the venom of a cone shell. It treats pain by blocking the transmission of pain along the peripheral nervous system, say the researchers, from the University of Melbourne (Australia; www.unimelb.edu.au). At least one other company has already developed a drug for pain from a cone shell toxin (conotoxin), but it has shown side effects that include raised blood pressure. ACV1 acts on a different class of pain receptors and is unlikely to exhibit the same side effects.

"ACV1 is a tiny molecule compared to competing conotoxin drugs, making it easier and cheaper to synthesize,” said Bruce Livett, team leader and an associate professor in the department of biochemistry and molecular biology at the University of Melbourne. "Competing drugs also need to be injected into the spinal column. ACV1 can be injected into the muscle or fat layer of patients, making it available to a wider group of patients and an advantage when recruiting patients for clinical trials.”




Related Links:
U. of Melbourne

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.